|
|
Article: OTHER NEW TO NOTE.
- Article from:
- BIOWORLD Today
- Article date:
- February 24, 2006
CopyrightCOPYRIGHT 2006 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Arisaph Pharmaceuticals Inc., of Boston, granted a nonexclusive, worldwide license under its DPP-IV portfolio to an undisclosed U.S. drug discovery and development company. The patent estate covers the use of DPP-IV inhibitors for the treatment of diabetes and lowering glucose levels. Under the terms, Arisaph received a significant up-front payment, and is eligible for milestones and royalties. Specific terms were not disclosed.
BioPartners GmbH, of Baar, Switzerland, received a positive opinion from the European Medicines Agency's Committee on Medicinal Products for Human Use for Valtropin, its product candidate containing recombinant human growth hormone. If ...